Background and Objectives

This clinical trial targets patients with severe Sickle Cell Disease and beta-thalassemia. Conventional allogeneic hematopoietic stem cell transplantation has been limited due to its high toxicity. This study aims to reduce toxicity through partial transplantation. This approach has the potential to significantly improve patients' quality of life by decreasing their dependence on blood transfusions.

Trial Design and Progress

The trial is currently in PHASE 1 and PHASE 2, with recruitment ongoing since June 18, 2026. Partial transplantation is being conducted at a slightly higher intensity than previous regimens, with the goal of increasing the proportion of donor cells. Specific primary endpoints and the anticipated completion date have not yet been disclosed.

Differentiation from Existing Treatments

The standard treatment involves blood transfusions and medications (e.g., hydroxyurea), while allogeneic hematopoietic stem cell transplantation carries a high risk of transplant-related mortality. This partial transplantation aims to maintain the benefits of hematopoietic stem cell transplantation while minimizing toxic side effects. If successful, it could provide long-term hematological stability compared to existing treatments.

Expected Outcomes and Impact

If the proportion of donor cells is sustained, patients will experience a significant reduction in their lifelong need for blood transfusions. This could lead to reduced healthcare costs and improved quality of life for patients. Furthermore, the partial transplantation technique may be applicable to other hematological disorders.